Login to Your Account

Full, Partial, Gamma, Delta . . .

PPAR for the Course in Diabetes? Tweakers of Class Not Giving Up

By Randy Osborne

Monday, January 11, 2010
With the FDA's Jan. 16 action date approaching for MannKind Corp.'s inhaled insulin Afresa, Wall Street grows less and less excited about the prospects for anything actually happening, given the agency's "glacial pace" - in the words of analysts at Hapoalim Securities - and the lack of an advisory panel for the Exubera-spooked candidate.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription